Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

Area of Science:

• Immunology
• Allergology
• Pharmacology

Background:

• Allergic rhinitis (AR) is a widespread nasal condition with significant public health implications.
• Existing treatments often inadequately control symptoms for many patients.
• Biologic therapies targeting type 2 inflammation have emerged for difficult-to-treat AR.

Purpose of the Study:

• To evaluate the efficacy and safety of biologic agents in AR management.
• To provide recommendations for the appropriate use of biologics in AR.
• To support the integration of biologics into clinical practice for uncontrolled AR.

Main Methods:

• A multidisciplinary expert panel convened to review current evidence.
• Evaluation of international and regional clinical studies on biologic therapies for AR.
• Focus on evidence for seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

Main Results:

• Biologic therapies show promise for patients with poorly controlled AR, especially SAR.
• Novel agents like stapokibart are advancing treatment options.
• Evidence for biologics in perennial allergic rhinitis (PAR) is still limited.

Conclusions:

• Biologics represent a valuable therapeutic option for specific AR patient populations.
• Standardized, evidence-based recommendations are needed for biologic use in AR.
• Further research is warranted, particularly for PAR, to optimize biologic therapy integration.